Market Executive Summary

The global viral clearance market is estimated to garner robust revenue by the end of 2033 by growing at a CAGR of ~XX% over the forecast period, i.e., 2023 – 2033. Further, the market generated impressive revenue in the year 2022. The growth of the market can primarily be attributed to the rising demand for specialty drugs across the globe. For instance, in 2020, the specialty drug expenditure was estimated to hit X% while in 2019, approximately XX% of the global population was projected to take at least 1 specialty drug.

Global viral clearance market trends such as, rising government initiatives in each country in favor of viral clearance along with spiking penetration of infectious lung diseases and noteworthy growth in healthcare expenditure are projected to influence the growth of the market positively over the forecast period. As per the statistics provided by the World Bank, it was noticed that healthcare expenditure dropped to USD 1,121.9 per capita in 2019. Viral clearance is the difference found between the quantity of virus in the input sample and the fraction containing the product after purification. Moreover, ongoing development in novel technology and rising awareness of viral safety is further expected to flourish the growth of the market over the forecast period. 

Global Viral Clearance Market: Growth Drivers and Challenges

Growth Drivers

• 
  

  Growing Prevalence of Infectious Diseases to Boost the Market Growth

  
  

Based on the report provided by the World Health Organization (WHO), it was noticed that around 50,000 people die every day owing to some infectious diseases worldwide.

Infectious diseases are caused by various fungi, bacteria, and viruses and can be life-threatening sometimes. Diseases and disorders associated with infections are triggered by certain organisms that require early diagnosis so that they can be healed before spreading to multiple parts of the body. Viral clearance becomes useful since it removes viral contamination utilizing membranes or chromatography.

• Increasing Cases of Chronic Disease

According to the Centers for Disease Control and Prevention, it was noticed that 6 in 10 Americans have at least 1 chronic disease.

• Rising Demand for Viral Clearance in Non-Communicable Diseases

World Health Organization (WHO) stated that non-communicable diseases cause nearly 17.9 million people per year.

• Significant Increment in the Number of Viral Fevers

For instance, more than 150 million dengue virus infections are diagnosed every year across the globe.

Challenges

• Long-Lasting Development Procedure for Drug Discovery


• Lack of the Requisite Medical Workforce


• Requirement for Higher Initial Investment

The global viral clearance market is segmented and analyzed for demand and supply by end-user into CROs, pharmaceuticals, and biotechnology companies, out of which, the CROs segment is projected to witness noteworthy growth over the forecast period. The growth of the segment can be accounted to the rising investment in the R&D of new medical technology and medicine. For instance, the total spending on medicine across the world is evaluated at around USD 1 trillion in 2021.

Global Viral Clearance Market Regional Synopsis

Regionally, the global viral clearance market is studied into five major regions including North America, Europe, Asia Pacific, Latin America and Middle East & Africa region. Amongst these markets, the market in the North America region is projected to hold the largest market share by the end of 2033. The growth of the market in the region can be ascribed to the presence of major key players in the region and the escalation in number of drug approval. As of 2021, nearly 48 novel drugs were approved by the United States Federal Drug Association (FDA) which was an increase from the recent decade when 24 drugs were being approved per year. Moreover, a higher number of CROs facilitating clinical and preclinical services is further estimated to hike the growth of the market during the forecast period.

The global viral clearance market is further classified on the basis of region as follows:

• North America (U.S. & Canada) Market size, Y-O-Y growth, Market Players Analysis & Opportunity Outlook


• Latin America (Brazil, Mexico, Argentina, Rest of Latin America) Market size, Y-O-Y growth, Market Players Analysis & Opportunity Outlook


• Europe (U.K., Germany, France, Italy, Spain, Hungary, Belgium, Netherlands & Luxembourg, NORDIC (Finland, Sweden, Norway, Denmark), Ireland, Switzerland, Austria, Poland, Turkey, Russia, Rest of Europe), Poland, Turkey, Russia, Rest of Europe) Market size, Y-O-Y growth, Market Players Analysis & Opportunity Outlook


• Asia-Pacific (China, India, Japan, South Korea, Singapore, Indonesia, Malaysia, Australia, New Zealand, Rest of Asia-Pacific) Market size, Y-O-Y growth, Market Players Analysis & Opportunity Outlook


• Middle East and Africa (Israel, GCC (Saudi Arabia, UAE, Bahrain, Kuwait, Qatar, Oman), North Africa, South Africa, Rest of Middle East and Africa) Market size, Y-O-Y growth, Market Players Analysis & Opportunity Outlook

Market Segmentation

Our in-depth analysis of the global viral clearance market includes the following segments:

By Method	Viral Inactivation Viral Removal
By Application	Blood Recombination Vaccine
By End-User	CROs Pharmaceuticals Biotechnology Company

Key Players:

• Labor Dr. Merk & Kollegen GmbH

• Texcell Inc.


• Merck KGaA


• Charles River Laboratories, Inc.


• Sartorius AG


• SGS AG


• Syngene International Limited


• Lonza AG


• Kedrion S. p. A.


• Merieux NutriSciences Corporation